<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-10-20" updated="2019-12-02">
  <drugbank-id primary="true">DB09208</drugbank-id>
  <name>Pegloticase</name>
  <description>Pegloticase is a recombinant porcine-like uricase drug indicated for the treatment of severe, treatment-refractory, chronic gout. Similarly to rasburicase, pegloticase metabolises the conversion of uric acid to allantoin. This reduces the risk of precipitate formation and development of gout, since allantoin is five to ten times more soluble than uric acid. Pegloticase is a pegylated form of uricase which offers an extended half-life of ten-12 days compared to rasburicase's 8 hours. It also offers reduced immunogenicity due to the bulky PEG group. The longer haf-life allows for less frequent dosing at once every 2-4 weeks making pegloticase more convenient for chronic use.</description>
  <cas-number>885051-90-1</cas-number>
  <unii>R581OT55EA</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A18541</ref-id>
        <pubmed-id>27493693</pubmed-id>
        <citation>Sattui SE, Gaffo AL: Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. doi: 10.1177/1759720X16646703.  Epub 2016 May 2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of chronic gout in adult patients refractory to conventional therapy.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Pegloticase is a recombinant uricase that catalyzes the metabolism of uric acid to allantoin.</mechanism-of-action>
  <toxicity>Conditions that should be monitored for when starting treatment with pegloticase include anaphylaxis, infusion reactions, an increase in gout flares,  and/or an exacerbation of pre-existing congestive heart failure. </toxicity>
  <metabolism/>
  <absorption>Approximately 24 hours following the first dose, mean plasma uric acid levels were 0.7 mg/dL. The duration of suppression of plasma uric acid appeared to be positively associated with pegloticase dose. Sustained decrease in plasma uric acid below the solubility concentration of 6 mg/dL for more than 300 hours was observed with doses of 8 mg and 12 mg.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Puricase</synonym>
  </synonyms>
  <products>
    <product>
      <name>Krystexxa</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60809-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>8 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125293</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Krystexxa</name>
      <labeller>Crealta Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002208</ema-product-code>
      <ema-ma-number>EU/1/12/810/001</ema-ma-number>
      <started-marketing-on>2013-01-08</started-marketing-on>
      <ended-marketing-on>2016-07-22</ended-marketing-on>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>8 mg/ml</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Krystexxa</name>
      <labeller>Savient Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>54396-801</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>8 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125293</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Krystexxa</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75987-080</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-09-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>8 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125293</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Krystexxa</name>
      <ingredients>Pegloticase</ingredients>
    </mixture>
    <mixture>
      <name>Krystexxa</name>
      <ingredients>Pegloticase</ingredients>
    </mixture>
    <mixture>
      <name>Krystexxa</name>
      <ingredients>Pegloticase</ingredients>
    </mixture>
    <mixture>
      <name>Krystexxa</name>
      <ingredients>Pegloticase</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Antigout Preparations</category>
      <mesh-id>D006074</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Enzymes, Immobilized</category>
      <mesh-id>D004800</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Musculo-Skeletal System</category>
      <mesh-id/>
    </category>
    <category>
      <category>Oxidoreductases</category>
      <mesh-id>D010088</mesh-id>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Uric Acid-specific Enzyme</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>8 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>8 mg/ml</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="M04AX02">
      <level code="M04AX">Other antigout preparations</level>
      <level code="M04A">ANTIGOUT PREPARATIONS</level>
      <level code="M04">ANTIGOUT PREPARATIONS</level>
      <level code="M">MUSCULO-SKELETAL SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09208.pdf?1445369768</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB04854</drugbank-id>
      <name>Febuxostat</name>
      <description>The risk or severity of adverse effects can be increased when Febuxostat is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with GlycoPEG-GCSF.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegpleranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegsunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginesatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>The risk or severity of adverse effects can be increased when Allopurinol is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The risk or severity of adverse effects can be increased when Probenecid is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The risk or severity of adverse effects can be increased when Tienilic acid is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of adverse effects can be increased when Azapropazone is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>The risk or severity of adverse effects can be increased when Lesinurad is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12319</drugbank-id>
      <name>Benzbromarone</name>
      <description>The risk or severity of adverse effects can be increased when Benzbromarone is combined with Pegloticase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13277</drugbank-id>
      <name>Benziodarone</name>
      <description>The risk or severity of adverse effects can be increased when Benziodarone is combined with Pegloticase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt; Pegloticase
TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVI
PTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVK
HVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKD
RCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLT
LGQVPEIEDMEISLPNIHYLNIDMSKMGLINKEEVLLPLDNPYGKITGTVKRKLSSRL</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>34192.8533</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1549H2430N408O448S8</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910417</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D09316</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pegloticase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1237025</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/krystexxa-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>https://www.drugs.com/cdi/pegloticase.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004823</id>
      <name>Uric acid</name>
      <organism>Humans</organism>
      <actions>
        <action>metabolizer</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>